Status:
UNKNOWN
A Non-invasive Model to Predict Antiviral Therapy in Gray Zone of Chronic Hepatitis B
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborating Sponsors:
Linyi People's Hospital
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Hepatitis B, Chronic
Eligibility:
All Genders
16-65 years
Brief Summary
Establishment and validation of the non-invasive model to predict antiviral therapy in the gray zone of chronic hepatitis B
Detailed Description
Chronic hepatitis B virus (HBV) infection continues to be a major public health problem worldwide today. According to statistics, the prevalence of chronic HBV infection assessed globally in 2016 was ...
Eligibility Criteria
Inclusion
- HBeAg positive, normal serum alanine aminotransferase(ALT) level，HBVDNA≤10\^6 IU/ml
- HBeAg positive, elevated serum ALT, HBVDNA≤2\*10\^4 IU/ml
- HBeAg negative, elevated serum ALT, HBVDNA≤2\*10\^3 IU/ml
- HBeAg negative, normal serum ALT, HBVDNA≥2\*10\^3 IU/ml
- Normal upper limit of ALT is 35 U/L for male and 25 U/L for female.
Exclusion
- Concurrent with other liver diseases such as autoimmune hepatitis, Hepatitis C virus infectious, liver cirrhosis, HCC, or unexplained liver function abnormalities
- Patients with incomplete clinical data
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06041022
Start Date
October 1 2023
End Date
December 31 2023
Last Update
September 18 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.